GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Net Current Asset Value

TRDA (Entrada Therapeutics) Net Current Asset Value : $8.80 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Entrada Therapeutics's net current asset value per share for the quarter that ended in Mar. 2025 was $8.80.

The historical rank and industry rank for Entrada Therapeutics's Net Current Asset Value or its related term are showing as below:

TRDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.84   Med: 2.2   Max: 4.87
Current: 0.84

During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Entrada Therapeutics was 4.87. The lowest was 0.84. And the median was 2.20.

TRDA's Price-to-Net-Current-Asset-Value is ranked better than
88.83% of 985 companies
in the Biotechnology industry
Industry Median: 3.92 vs TRDA: 0.84

Entrada Therapeutics Net Current Asset Value Historical Data

The historical data trend for Entrada Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entrada Therapeutics Net Current Asset Value Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial -1.59 9.34 5.43 4.27 9.11

Entrada Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.14 9.08 8.91 9.11 8.80

Competitive Comparison of Entrada Therapeutics's Net Current Asset Value

For the Biotechnology subindustry, Entrada Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entrada Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Price-to-Net-Current-Asset-Value falls into.


;
;

Entrada Therapeutics Net Current Asset Value Calculation

Entrada Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(440.039-97.643-0-0)/37.575
=9.11

Entrada Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(403.193-69.219-0-0)/37.942
=8.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entrada Therapeutics  (NAS:TRDA) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Entrada Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Entrada Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Executives
Kory James Wentworth officer: Chief Financial Officer 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Natarajan Sethuraman officer: Chief Scientific Officer 6 TIDE STREET, BOSTON MA 02210
Nathan J Dowden officer: Chief Operating Officer 6 TIDE STREET, BOSTON MA 02210
Dipal Doshi director, officer: President and CEO C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Peter S Kim director ONE MERCK DRIVE, P.O. BOX 100, WHITEHOUSE STATION X1 08889
Nerissa Kreher officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman director C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Bernhardt G Zeiher director ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
John F Crowley director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512